Sanofi And Regeneron Leapfrog Amgen In New Cholesterol Drug Race

January 26, 2015 7:47 AM

5 0

Early on Monday Sanofi and Regeneron leapfrogged their rival Amgen to gain leadership in the race to bring a new class of cholesterol drugs to market. The new development could potentially give Sanofi and Regeneron a month on the market by itself before facing competition from Amgen.

Sanofi and Regeneron announced early on Monday that the FDA had accepted for priority review the Biologics License Application (BLA) for alirocumab, their PCSK9 inhibitor. The six month priority review prescribed by the Prescription Drug User Fee Act (PDUFA) yields a target action date of July 24, ...

Also watch: 'SNL' recap: Trump doesn't accept election results there, either

Read more

To category page